Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NoBiasFluors

Financiado

Cerrado

Non biased fluorescent dyes as markers of drugs for optical in cellulo and in vi...

Non biased fluorescent dyes as markers of drugs for optical in cellulo and in vivo imaging Imaging of distribution of drugs in mice delivers accurate information for confirmation that the mechanism of action elaborated in cell-based assays is also operative in vivo. These data are critical for the transfer of drug disco... ver más

31/12/2024

FAU

699K€

Presupuesto del proyecto: 699K€

Líder del proyecto

FRIEDRICHALEXANDERUNIVERSITAET ERLANGENNUERNB... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 8 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-12-31

MSCA-RISE-2019: Research and Innovation Staff Excha...

I+D

Cerrada hace 5 años

0% 96% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

8 Participantes

FAU

133.40K€ | Lider

NOEL ALIMENTARIA

621.27K€ | Participante

CNR

92.00K€ | Participante

THE REGENTS OF THE UNIVERSIT...

Proyectos interesantes

PET3D

Medical Technol...

Data Science

4M€ Cerrado

BIO-LINKER

Medical Technol...

Data Science

150K€ Cerrado

IB4SD-TRISTAN

Medical Technol...

Data Science

23M€ Cerrado

EQC2021-007516-P

Medical Technol...

Data Science

654K€ Cerrado

ELSWIFLUOPRO

Medical Technol...

Data Science

185K€ Cerrado

PCI2024-153519

Medical Technol...

Data Science

135K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 62 meses Fecha Inicio: 2019-10-23
Fecha Fin: 2024-12-31

Líder del proyecto

FRIEDRICHALEXANDERUNIVERSITAET ERLANGENNUERNB... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 699K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Imaging of distribution of drugs in mice delivers accurate information for confirmation that the mechanism of action elaborated in cell-based assays is also operative in vivo. These data are critical for the transfer of drug discovery process from pre-clinical to clinical phase. To enable the imaging, drugs should be labeled with easily detectable moieties, e.g. radioactive markers and fluorescent dyes. Ideally, the markers should not affect in vivo properties of the drugs that can be better achieved with radioactive markers, since they can be selected to be small: e.g. a single atom marker 18F applied in positron emission tomography. Despite this intrinsic advantage, PET suffers from safety issues, since radioactivity is harmful to humans and environment. In terms of safety optical imaging is much better and, therefore, in future can replace PET. However, fluorescent dyes compatible with the optical imaging are usually extended pi-systems carrying overall positive or negative charge. Their conjugation strongly affects properties of the majority of medium sized and low molecular weight drugs that limits the applicability of this method in drug discovery. The interdisciplinary and intersectoral consortium NoBiasFluors consisting of 4 academic and 2 industrial teams aims at achieving a breakthrough solution of this problem. We will develop non-biased red and near infrared fluorescent dyes, which are compatible with in vivo optical imaging and do not affect properties of drugs upon their conjugation. This goal will be achieved by the careful optimization of dye structure, polarity and charge. We will confirm the functionality of the developed dyes for labeling of representative drugs (anticancer N-alkylaminoferrocene-based prodrugs, D-peptides targeting Alzheimer’s disease) and binders of biomolecules (nucleopeptides and lectins) and monitoring their distribution both in cellulo and in vivo (for a selected labeled drug).

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores